As a part of the annual Russell Index reconstitution, this ‘Strong Buy’-rated penny stock is one of the new entrants to the Russell 2000 Index.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...
/PRNewswire/ -- Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023,...
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and...
/PRNewswire/ -- PharmaVentures announces its new office in Korea as part of its continued strategic expansion Headquartered in London, UK, PharmaVentures has...
ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”)....
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the Cowen 43 rd Annual Health Care Conference in Boston, MA, on Tuesday,...
ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided business updates.